Patents Assigned to HUYA BIOSCIENCE INTERNATIONAL LLC
  • Sulcardine salts
    Patent number: 11020374
    Abstract: Sulcardine salts other than sulfuric acid salts of sulcardine, including crystalline sulcardine salts, are provided herein. Pharmaceutical compositions comprising such salts and methods of treating arrhythmias comprising administering effective amounts of such salts are also provided.
    Type: Grant
    Filed: October 23, 2020
    Date of Patent: June 1, 2021
    Assignee: HUYA Bioscience International, LLC
    Inventors: Suzanne J. Romano, Hayley Ann Reece, Joseph Edward Gordon Benson, Sarah Collins, Gary T. Elliott, Mireille Gillings, Robert Goodenow, Curtis Tyree
  • Combination therapies of HDAC inhibitors and PD-L1 inhibitors
    Patent number: 10385131
    Abstract: Provided herein are combinations that include an HDACi and a PD-L1 inhibitor that are useful for treating cancer, including cancer resistant to PD-1 inhibitors.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 20, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Combination therapies of HDAC inhibitors and PD-1 inhibitors
    Patent number: 10385130
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Grant
    Filed: May 11, 2017
    Date of Patent: August 20, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Combination therapies of HDAC inhibitors and PD-1 inhibitors
    Patent number: 10287353
    Abstract: Provided herein are combinations that include an HDACi and a PD-1 inhibitor that are useful for treating cancer, including reducing and/or preventing cancer metastasis. The combination is also useful for treating cancer that has been previously treated with a PD-L1 inhibitor.
    Type: Grant
    Filed: August 14, 2018
    Date of Patent: May 14, 2019
    Assignee: HUYA Bioscience International, LLC
    Inventors: Reid P. Bissonnette, Alain Rolland, Mireille Gillings
  • Slow infusion of sulcardine and its salts
    Patent number: 8637566
    Abstract: A composition comprised of an active agent that is 4-methoxy-N-(3,5-bis-(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide or a pharmaceutically acceptable salt thereof is intravenously administered to a subject, substantially evenly over a period of greater than about 15 minutes, to avoid disadvantageous hemodynamic effects, including systemic diastolic and systolic hypotension, to can occur with rapid intravenous or even short-term infusion administration of the active agent.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: January 28, 2014
    Assignee: HUYA Bioscience International LLC
    Inventor: Gary T. Elliott
  • PURIFIED CARDIOGENIN ISOMER AND RELATED METHODS
    Publication number: 20130345159
    Abstract: A cardiogenin major isomer is obtained from a methanol extract of Geum japonicum and separated from its minor isomer. The separation of the two isomers can be achieved by chiral phase chromatography, e.g., using a Chiralpak® IC™ column. The purity of the isolated cardiogenin major isomer can be further increased by crystallization, yielding isolated cardiogenin major isomer having HPLC purity as high as 98.97% (a/a) at 210 nm and a potency of 95.50%) (w/w).
    Type: Application
    Filed: December 21, 2011
    Publication date: December 26, 2013
    Applicant: HUYA BIOSCIENCE INTERNATIONAL LLC
    Inventors: Andreas Kyas, Ernst Freund, Oliver Schlörke, Joerg Lill, Lars Rogall, Dario Menia, Gary Elliott, James Paterniti
  • Treatment of atrial fibrillation
    Patent number: 8541464
    Abstract: Atrial fibrillation (AF) can be treated or prevented by administering to a subject who suffers from or is at risk of suffering from AF a composition comprised of an amount of an active agent, which is 4-methoxy-N-(3,5-bis(1-pyrrolidinyl)-4-hydroxy benzyl)benzene sulfonamide (sulcardine) or a pharmaceutically acceptable salt thereof, such that the Cmax value the active agent in the subject is in the range from about 1 ?M to about 20 ?M.
    Type: Grant
    Filed: November 16, 2010
    Date of Patent: September 24, 2013
    Assignee: HUYA Biosciences International LLC
    Inventor: Gary T. Elliott